Methods for treatment of sickle cell anemia

Details Methods for treatment of sickle cell anemia Methods for treatment of sickle cell anemia

1999-04-20

2001-06-26

Reamer, James H. (Department: 1614)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S371000

Reexamination Certificate

active

06251927

ABSTRACT:

FIELD OF THE INVENTION
The present invention generally relates to methods for treating anemia. More specifically, the present invention relates to methods for treating sickle cell anemia using protected forms(s) of organic aldehydes.
BACKGROUND OF THE INVENTION
Sickle cell disease is a hemolytic disorder, which affects, in its most severe form, approximately 80,000 patients in the United States (see, for example, D. L. Rucknagel, in R. D. Levere, Ed.,
Sickle Cell Anemia and Other Hemoglobinopathies
, Academic Press, New York, 1975, p.1). The disease is caused by a single mutation in the hemoglobin molecule; &bgr;6 glutamic acid in normal adult hemoglobin A is changed to valine in sickle hemoglobin S. (see, for example, V. M. Ingram in
Nature
, 178:792-794 (1956)). Hemoglobin S has a markedly decreased solubility in the deoxygenated state when compared to that of hemoglobin A. Therefore, upon deoxygenation, hemoglobin S molecules within the erythrocyte tend to aggregate and form helical fibers that cause the red cell to assume a variety of irregular shapes, most commonly in the sickled form. After repeated cycles of oxygenation and deoxygenation, the sickle cell in the circulation becomes rigid and no longer can squeeze through the small capillaries in tissues, resulting in delivery of insufficient oxygen and nutrients to the organ, which eventually leads to local tissue necrosis. The prolonged blockage of microvascular circulation and the subsequent induction of tissue necrosis lead to various symptoms of sickle cell anemia, including painful crises of vaso-occlusion.
Now, most patients with sickle cell disease can be expected to survive into adulthood, but still face a lifetime of crises and complications, including chronic hemolytic anemia, vaso-occlusive crises and pain, and the side effects of therapy. Currently, most common therapeutic interventions include blood transfusions, opioid and hydroxyurea therapies (see, for example, S. K. Ballas in
Cleveland Clin. J. Med
., 66:48-58 (1999). However, all of these therapies are associated with some undesirable side-effects. For example, repeated blood transfusions are known to be associated with the risks of transmission of infectious disease, iron overload, and allergic and febrile reactions. Complications of opioid therapy may include addiction, seizures, dependency, respiratory depression and constipation.
Hydroxyurea, an inhibitor of ribonucleotide reductase, acts by impairing DNA synthesis in cells (see, for example, J. W., Yarbro in
Semin. Oncol
., 19:1-10 (1992). For decades, hydroxyurea has been used clinically as an anti-cancer agent for the treatment of leukemia, skin and other cancers. Since early 1980, hydroxyurea has been used to treat patients with sickle cell disease. Sickle cell patients treated with hydroxyurea often seem to have fewer painful crises of vaso-occlusion, fewer hospitalizations and fewer episodes of acute chest syndrome (See, for example, S. Charache et al. in
New Engl. J. Med
., 332:1317-1322 (1995); S. Charache et al. in
Med
., 75:300-326 (1996); and J. L. Bauman et al. in
Arch. Intern Med
., 141:260-261 (1981)). It appears that hydroxyurea treatment increases fetal hemoglobin levels in the red cell, which in turn inhibits the aggregation of sickle cell hemoglobin. However, not all patients in these studies benefited from hydroxyurea treatment, and painful crises of vaso-occlusion were not eliminated in most patients. In fact, a recent clinical trial showed that after a 2-year treatment, fetal hemoglobin levels of patients assigned to the hydroxyurea arm of the study did not differ markedly from their pretreatment levels (see, for example, S. Charache in
Seminars in Hematol
, 34:15-21 (1997)). Thus, the mechanism of action of hydroxyurea in the treatment of sickle cell anemia remains unclear.
In addition to the limited effectiveness of hydroxyurea therapy, such treatment causes a wide range of undesirable side-effects. The primary side-effect of hydroxyurca is myelosuppression (neutropenia and thrombocytopenia), placing patients at risks for infection and bleeding. In addition, long-term treatment with hydroxyurea may cause a wide spectrum of diseases and conditions, including multiple skin tumors and ulcerations, fever, hepatitis, hyperpigmentation, scaling, partial alopecia, atrophy of the skin and subcutaneous tissues, nail changes and acute interstitial lung disease (see, for example, P. J. M. Best et al. in
Mayo Clin. Proc
., 73:961-963 (1998); M. S. Kavuru et al. in
Cerebral Arterial Thrombosis
, 87:767-769 (1994); M. J. F. Starmans-Kool et al. in
Ann. Hematol
., 70:279-280 (1995); and M. Papi et al. in
Am Acad. Dermatol
., 28:485-486 (1993)).
Since sickle cell disease is a genetic disease, in theory, the gene therapy approach should be considered. In fact, gene therapies employing either ribozyme-mediated or retroviral vector-mediated approaches to replacing the defective human &bgr;-globin gene are being actively developed for the treatment of sickle cell disease (see, for example, D. J. Weatherall,
Curr. Biol
., 8:R696-8 (1998); and R. Pawliuk et al.,
Ann. N.Y. Acad. Sci
., 850:151-162 (1998)). However, the gene therapy approach to treating sickle cell disease involves bone marrow transplantation, a procedure which has its own inherent toxicities and risks (for a review, see, C. A. Hillery in
Curr. Opin. Hematol
., 5:151-5 (1998)). Thus, there is still a need to develop new and more effective therapeutic agents against sickle cell disease.
The solution behavior of hemoglobin S can be modified chemically, particularly to change its low oxygen affinity and tendency to aggregate upon deoxygenation. Among various covalent modifications, blocking of amino groups of hemoglobin, which can bc accomplished under mild conditions, seems to be most favorable and pharmaceutically acceptable. For instance, vanillin (4-hydroxy-3-methoxybenzaldehyde) and other related aromatic aldehydes under physiological conditions are known to bind to the free amino groups of hemoglobin S via the classic Schiff base formation as follows (see, for example, R. H. Zaugg et al. in
J. Biol. Chem
., 252:8542-8548 (1977)):
Hb—NH
2
+R—CHO&rlarr2;Hb—N═CH—R+H
2
O.
Vanillin is a flavorant present in foods and beverages and has been granted GRAS (generally regarded as safe) compound status by the FDA. No toxicity was observed when vanillin was given to rats at high levels for extensive periods (see, for example, E. C. Hagan et al. in
Food Cosmet. Toxicol
., 5:141 (1967)). For example, no significant differences were observed between test and control rats with respect to body and organ weights, hematology, and histopathology when rats received vanillin at 1.0% of the diet for 16 weeks, 2.0% and 5.0% for 1 year, or 0.5%, 1.0% and 2.0% for 2 years.
Schiff base formation between hemoglobin S and vanillin produced a marked increase in oxygen affinity and shifts the oxy &rlarr2; deoxy equilibrium in favor of the oxy form for hemoglobin S, both in solution and in intact red cells. The locations where vanillin binds to hemoglobin S have also been characterized by X-ray crystallography (see, for example, D. J. Abraham et al. in
Am. J. Hematol
., 77:1334-1341 (1991)). Vanillin was shown to bind near His 103&agr;, Cys 104&agr; and Gln 131&bgr;, with a secondary binding site located between His 116&bgr; and His 117&bgr;, a site that has been implicated as a polymer contact residue. Ektacytometric studies also demonstrated that vanillin can inhibit the polymerization process of hemoglobin S under deoxygenated conditions (see, for example, Abraham et al. supra). Together, these studies indicate that vanillin may exhibit two related mechanisms of action as a potential antisickling agent. It not only inhibits sickle polymerization formation, but also shifts the hemoglobin-oxygen association curve to the left, with an increase in the solubility of hemoglobin S molecules. Both mechanisms could lead to the reduction of vaso-occlusion episodes.
Hemoglobin concentration within red cells is about 5 mmoles/liter. Ass

Affiliated with

Also associated with

Rating

Methods for treatment of sickle cell anemia does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods for treatment of sickle cell anemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods for treatment of sickle cell anemia will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2441230